Cogent Biosciences, Inc.
US ˙ NasdaqGS ˙ US19240Q2012

Introduction

This page provides a comprehensive analysis of the known insider trading history of Andrew R Robbins. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Andrew R Robbins has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:HARP / Harpoon Therapeutics, Inc. Director 0
US:COGT / Cogent Biosciences, Inc. President and CEO, Director 690,000
US:04269XAA3 / Array BioPharma Inc. Bonds 3.0% 6/1/2020 COO 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Andrew R Robbins. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases COGT / Cogent Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in COGT / Cogent Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

COGT / Cogent Biosciences, Inc. Insider Trades
Insider Sales COGT / Cogent Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in COGT / Cogent Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

COGT / Cogent Biosciences, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Andrew R Robbins as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-03-11 2024-03-11 4 HARP Harpoon Therapeutics, Inc.
Common Stock
D - Sale to Issuer -5,000 0 -100.00
2023-11-28 2023-11-27 4 HARP Harpoon Therapeutics, Inc.
Common Stock
A - Award 5,000 5,000
2022-01-27 2022-01-25 4 COGT Cogent Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 690,000 690,000 4.94 3,410,808 3,410,808
2021-05-14 2021-05-04 4/A HARP Harpoon Therapeutics, Inc.
Director Stock Option (Right to Buy)
A - Award 10,167 10,167
2021-05-07 2021-05-04 4 HARP Harpoon Therapeutics, Inc.
Director Stock Option (Right to Buy)
A - Award 10,167 10,167
2021-02-12 2021-02-10 4 COGT Cogent Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 315,200 315,200
2020-12-09 2020-12-07 4 COGT Cogent Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 456,693 456,693
2020-10-27 2020-10-23 4 COGT Cogent Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 7,442,421 7,442,421
2020-04-01 2020-03-30 4 HARP Harpoon Therapeutics, Inc.
Director Stock Option (right to buy)
A - Award 20,335 20,335
2019-07-30 2019-07-30 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
D - Sale to Issuer -315,750 0 -100.00
2019-07-30 2019-07-30 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
D - Sale to Issuer -335,250 0 -100.00
2019-07-30 2019-07-30 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
D - Sale to Issuer -313,989 0 -100.00
2019-07-30 2019-07-30 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
D - Sale to Issuer -236,250 0 -100.00
2019-07-30 2019-07-30 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
D - Sale to Issuer -236,250 0 -100.00
2019-07-30 2019-07-30 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
D - Sale to Issuer -12,500 0 -100.00
2019-07-30 2019-07-30 4 ARRY ARRAY BIOPHARMA INC
Common Stock
D - Sale to Issuer -130,542 0 -100.00
2019-07-30 2019-07-30 4 ARRY ARRAY BIOPHARMA INC
Common Stock
D - Sale to Issuer -71,022 130,542 -35.24 48.00 -3,409,056 6,266,016
2019-04-03 2019-04-01 4 ARRY ARRAY BIOPHARMA INC
Restricted Stock Units
M - Exercise -9,844 9,844 -50.00
2019-04-03 2019-04-01 4 ARRY ARRAY BIOPHARMA INC
Restricted Stock Units
M - Exercise -9,844 9,844 -50.00
2019-04-03 2019-04-01 4 ARRY ARRAY BIOPHARMA INC
Common Stock
F - Taxes -8,660 71,022 -10.87 24.60 -213,036 1,747,141
2019-04-03 2019-04-01 4 ARRY ARRAY BIOPHARMA INC
Common Stock
M - Exercise 19,688 79,682 32.82
2019-02-08 2019-02-06 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
M - Exercise -87,500 0 -100.00
2019-02-08 2019-02-06 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
M - Exercise -37,500 12,500 -75.00
2019-02-08 2019-02-06 4 ARRY ARRAY BIOPHARMA INC
Common Stock
S - Sale -239,626 59,994 -79.98 20.02 -4,798,511 1,201,380
2019-02-08 2019-02-06 4 ARRY ARRAY BIOPHARMA INC
Common Stock
M - Exercise 87,500 299,620 41.25 4.63 405,125 1,387,241
2019-02-08 2019-02-06 4 ARRY ARRAY BIOPHARMA INC
Common Stock
M - Exercise 37,500 212,120 21.48 8.20 307,500 1,739,384
2018-12-18 2018-12-16 4 ARRY ARRAY BIOPHARMA INC
Restricted Stock Units
M - Exercise -13,968 41,907 -25.00
2018-12-18 2018-12-16 4 ARRY ARRAY BIOPHARMA INC
Restricted Stock Units
M - Exercise -13,083 26,166 -33.33
2018-12-18 2018-12-16 4 ARRY ARRAY BIOPHARMA INC
Common Stock
F - Taxes -11,898 174,620 -6.38 15.97 -190,011 2,788,681
2018-12-18 2018-12-16 4 ARRY ARRAY BIOPHARMA INC
Common Stock
M - Exercise 27,051 186,518 16.96
2018-12-18 2018-12-14 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
A - Award 315,750 315,750
2018-12-18 2018-12-14 4 ARRY ARRAY BIOPHARMA INC
Restricted Stock Units
A - Award 52,625 52,625
2018-06-29 2018-06-27 4 ARRY ARRAY BIOPHARMA INC
Restricted Stock Units
M - Exercise -32,068 0 -100.00
2018-06-29 2018-06-27 4 ARRY ARRAY BIOPHARMA INC
Common Stock
S - Sale X -17,964 159,467 -10.12 17.74 -318,681 2,828,945
2018-06-29 2018-06-27 4 ARRY ARRAY BIOPHARMA INC
Common Stock
F - Taxes -14,104 177,431 -7.36 18.50 -260,924 3,282,474
2018-06-29 2018-06-27 4 ARRY ARRAY BIOPHARMA INC
Common Stock
M - Exercise 32,068 191,535 20.11
2018-04-03 2018-04-01 4 ARRY ARRAY BIOPHARMA INC
Restricted Stock Units
M - Exercise -9,844 19,688 -33.33
2018-04-03 2018-04-01 4 ARRY ARRAY BIOPHARMA INC
Common Stock
F - Taxes -8,675 159,467 -5.16 16.32 -141,576 2,602,501
2018-04-03 2018-04-01 4 ARRY ARRAY BIOPHARMA INC
Common Stock
M - Exercise 9,844 168,142 6.22
2017-12-19 2017-12-18 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
M - Exercise -87,500 87,500 -50.00
2017-12-19 2017-12-18 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
M - Exercise -89,634 0 -100.00
2017-12-19 2017-12-18 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
M - Exercise -20,366 0 -100.00
2017-12-19 2017-12-18 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
M - Exercise -200,000 0 -100.00
2017-12-19 2017-12-18 4 ARRY ARRAY BIOPHARMA INC
Common Stock
S - Sale X -282,874 158,298 -64.12 10.72 -3,032,409 1,696,955
2017-12-19 2017-12-18 4 ARRY ARRAY BIOPHARMA INC
Common Stock
M - Exercise 87,500 441,172 24.74 4.63 405,125 2,042,626
2017-12-19 2017-12-18 4 ARRY ARRAY BIOPHARMA INC
Common Stock
M - Exercise 89,634 353,672 33.95 4.91 440,103 1,736,530
2017-12-19 2017-12-18 4 ARRY ARRAY BIOPHARMA INC
Common Stock
M - Exercise 20,366 264,038 8.36 4.91 99,997 1,296,427
2017-12-19 2017-12-18 4 ARRY ARRAY BIOPHARMA INC
Common Stock
M - Exercise 200,000 243,672 457.96 5.14 1,028,000 1,252,474
2017-12-19 2017-12-16 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
A - Award 335,250 335,250
2017-12-19 2017-12-16 4 ARRY ARRAY BIOPHARMA INC
Restricted Stock Units
A - Award 55,875 55,875
2017-12-19 2017-12-16 4 ARRY ARRAY BIOPHARMA INC
Restricted Stock Units
M - Exercise -13,082 39,249 -25.00
2017-12-19 2017-12-16 4 ARRY ARRAY BIOPHARMA INC
Common Stock
F - Taxes -6,094 43,672 -12.25 10.92 -66,546 476,898
2017-12-19 2017-12-16 4 ARRY ARRAY BIOPHARMA INC
Common Stock
M - Exercise 13,082 49,766 35.66
2017-04-06 2017-04-01 4/A ARRY ARRAY BIOPHARMA INC
Common Stock
F - Taxes -9,167 36,684 -19.99 8.94 -81,953 327,955
2017-04-04 2017-04-01 4 ARRY ARRAY BIOPHARMA INC
Restricted Stock Units
M - Exercise -9,843 29,532 -25.00
2017-04-04 2017-04-01 4 ARRY ARRAY BIOPHARMA INC
Common Stock
F - Taxes -6,293 39,558 -13.72 8.94 -56,259 353,649
2017-04-04 2017-04-01 4 ARRY ARRAY BIOPHARMA INC
Common Stock
M - Exercise 9,843 45,851 27.34
2016-12-29 2016-12-27 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
A - Award 313,989 313,989
2016-12-29 2016-12-27 4 ARRY ARRAY BIOPHARMA INC
Restricted Stock Units
A - Award 52,331 52,331
2016-04-05 2016-04-01 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
A - Award 236,250 236,250
2016-04-05 2016-04-01 4 ARRY ARRAY BIOPHARMA INC
Restricted Stock Units
A - Award 39,375 39,375
2016-04-05 2016-04-01 4 ARRY ARRAY BIOPHARMA INC
Common Stock
F - Taxes -3,367 36,008 -8.55 3.00 -10,101 108,024
2015-04-03 2015-04-01 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
A - Award 236,250 236,250
2015-04-03 2015-04-01 4 ARRY ARRAY BIOPHARMA INC
Common Stock
A - Award 39,375 39,375
2015-04-03 2015-03-02 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
A - Award 50,000 50,000
2015-03-04 2015-03-02 4 ARRY ARRAY BIOPHARMA INC
Common Stock
S - Sale -21,576 0 -100.00 8.25 -178,002
2015-03-04 2015-03-01 4 ARRY ARRAY BIOPHARMA INC
Restricted Stock Units
M - Exercise -32,069 32,069 -50.00
2015-03-04 2015-03-01 4 ARRY ARRAY BIOPHARMA INC
Common Stock
F - Taxes -10,493 21,576 -32.72 7.96 -83,524 171,745
2015-03-04 2015-03-01 4 ARRY ARRAY BIOPHARMA INC
Common Stock
M - Exercise 32,069 32,069 7.96 255,269 255,269
2014-08-20 2014-08-18 4 ARRY ARRAY BIOPHARMA INC
Restricted Stock Units
A - Award 64,137 64,137
2014-04-03 2014-04-01 4 ARRY ARRAY BIOPHARMA INC
Stock Option (Right to Buy)
A - Award 175,000 175,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)